ENTX Stock Forecast & Price Target

Entera Bio is well-positioned to advance its product candidates, with the next-generation formulation of EB613 entering clinical trials soon and a pivotal program to begin in late 2026, one year earlier than previous expectations. The company also plans to conduct a long-term extension study and has a potential launch date of 2029 for EB613. With a promising phase 1 trial for the refined N-Tab formulation, there is potential for improved PK and safety results, mitigating clinical development risk and increasing the commercial viability of this drug.

Entera Bio is a clinical-stage biopharmaceutical company that has developed an orally-delivered, potential treatment for osteoporosis, obesity, and short bowel syndrome. However, their products are still in the early stages of development and face competition in the market. Additionally, the company has reported losses and relies heavily on external funding, making them a high-risk investment.